利治疗公司筹集了155万美元的可转换债券, 用于研发. Sharp Therapeutics raises $1.55M in convertible notes to fund R&D.

利治疗公司报告了其第四季度和2025年全年的财务业绩,强调研究与开发支出增加80%,重点关注GBA1,尼曼·皮克C以及Progranulin疾病. Sharp Therapeutics Corp. reported its fourth quarter and full-year 2025 financial results, highlighting an 80% increase in research and development spending focused on GBA1, Niemann Pick C, and Progranulin disorders. 公司收购了五笔可转换债券,筹集155万美元,内部人士买下最后一笔. The company closed a five-tranche convertible note offering, raising $1.55 million, with insiders purchasing a portion of the final tranche. 收入将支持一般的营运资本需求. Proceeds will support general working capital needs. 此外,夏普宣布达成协议购买至少200万股票并计划采用半年报表. Additionally, Sharp announced an agreement to buy at least 2 million shares and plans to adopt semi-annual reporting.